Polymer-Based Paclitaxel-Eluting Coronary Stents

Clinical Results in de Novo Lesions

Alaide Chieffo, Antonio Colombo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Drug-eluting stents (DES) represent one of the fastest-growing fields in interventional cardiology today. Paclitaxel (Taxol) is a potent antiproliferative agent that shifts the microtubule equilibrium toward assembly, favoring the formation of abnormally stable microtubules with blockage of the cell cycle in G2/M phases. A series of clinical trials (TAXUS I through VI) have been designed to test the safety and the efficacy of polymer-based paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, MA, USA) at the dosage 1 μg/mm2 in a variety of clinical settings. Except for TAXUS III and TAXUS V-ISR, in the TAXUS program de novo lesions have been evaluated. Two different release kinetics were evaluated: slow-release (SR) and moderate-release (MR) formulation. Very encouraging preliminary results also come from the "real world" data on Taxus SR stent collected in the "Web-based taxus Intercontinental observational Data TransitiOnal registry program" (the WISDOM Registry) and in the "Real Life Polymer-Based Paclitaxel Registry" (the Real Life PBPaclitaxel Registry). The remarkable positive results obtained from the randomized trials offer the interventional cardiologist another effective option (besides the Cypher stent, Cordis a J & J, Warren, NJ, USA) to treat patients with a DES. This fact may certainly drive the competition and, ultimately, lower the cost. The final answer will probably come from the ongoing registries and prospective trials versus coronary artery bypass grafting (CABG), which will reveal the real impact of this new technology on everyday practice.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalHerz
Volume29
Issue number2
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Paclitaxel
Stents
Registries
Taxus
Polymers
Drug-Eluting Stents
Microtubules
G2 Phase
Cardiology
Coronary Artery Bypass
Cell Division
Cell Cycle
Clinical Trials
Technology
Safety
Costs and Cost Analysis

Keywords

  • De novo lesions
  • Paclitaxel-eluting stents
  • Restenosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Polymer-Based Paclitaxel-Eluting Coronary Stents : Clinical Results in de Novo Lesions. / Chieffo, Alaide; Colombo, Antonio.

In: Herz, Vol. 29, No. 2, 03.2004, p. 147-151.

Research output: Contribution to journalArticle

@article{1f2ff2fce72648ad9d55c3e2a5b8ef05,
title = "Polymer-Based Paclitaxel-Eluting Coronary Stents: Clinical Results in de Novo Lesions",
abstract = "Drug-eluting stents (DES) represent one of the fastest-growing fields in interventional cardiology today. Paclitaxel (Taxol) is a potent antiproliferative agent that shifts the microtubule equilibrium toward assembly, favoring the formation of abnormally stable microtubules with blockage of the cell cycle in G2/M phases. A series of clinical trials (TAXUS I through VI) have been designed to test the safety and the efficacy of polymer-based paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, MA, USA) at the dosage 1 μg/mm2 in a variety of clinical settings. Except for TAXUS III and TAXUS V-ISR, in the TAXUS program de novo lesions have been evaluated. Two different release kinetics were evaluated: slow-release (SR) and moderate-release (MR) formulation. Very encouraging preliminary results also come from the {"}real world{"} data on Taxus SR stent collected in the {"}Web-based taxus Intercontinental observational Data TransitiOnal registry program{"} (the WISDOM Registry) and in the {"}Real Life Polymer-Based Paclitaxel Registry{"} (the Real Life PBPaclitaxel Registry). The remarkable positive results obtained from the randomized trials offer the interventional cardiologist another effective option (besides the Cypher stent, Cordis a J & J, Warren, NJ, USA) to treat patients with a DES. This fact may certainly drive the competition and, ultimately, lower the cost. The final answer will probably come from the ongoing registries and prospective trials versus coronary artery bypass grafting (CABG), which will reveal the real impact of this new technology on everyday practice.",
keywords = "De novo lesions, Paclitaxel-eluting stents, Restenosis",
author = "Alaide Chieffo and Antonio Colombo",
year = "2004",
month = "3",
doi = "10.1007/s00059-004-2555-7",
language = "English",
volume = "29",
pages = "147--151",
journal = "Herz",
issn = "0340-9937",
publisher = "Urban und Vogel",
number = "2",

}

TY - JOUR

T1 - Polymer-Based Paclitaxel-Eluting Coronary Stents

T2 - Clinical Results in de Novo Lesions

AU - Chieffo, Alaide

AU - Colombo, Antonio

PY - 2004/3

Y1 - 2004/3

N2 - Drug-eluting stents (DES) represent one of the fastest-growing fields in interventional cardiology today. Paclitaxel (Taxol) is a potent antiproliferative agent that shifts the microtubule equilibrium toward assembly, favoring the formation of abnormally stable microtubules with blockage of the cell cycle in G2/M phases. A series of clinical trials (TAXUS I through VI) have been designed to test the safety and the efficacy of polymer-based paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, MA, USA) at the dosage 1 μg/mm2 in a variety of clinical settings. Except for TAXUS III and TAXUS V-ISR, in the TAXUS program de novo lesions have been evaluated. Two different release kinetics were evaluated: slow-release (SR) and moderate-release (MR) formulation. Very encouraging preliminary results also come from the "real world" data on Taxus SR stent collected in the "Web-based taxus Intercontinental observational Data TransitiOnal registry program" (the WISDOM Registry) and in the "Real Life Polymer-Based Paclitaxel Registry" (the Real Life PBPaclitaxel Registry). The remarkable positive results obtained from the randomized trials offer the interventional cardiologist another effective option (besides the Cypher stent, Cordis a J & J, Warren, NJ, USA) to treat patients with a DES. This fact may certainly drive the competition and, ultimately, lower the cost. The final answer will probably come from the ongoing registries and prospective trials versus coronary artery bypass grafting (CABG), which will reveal the real impact of this new technology on everyday practice.

AB - Drug-eluting stents (DES) represent one of the fastest-growing fields in interventional cardiology today. Paclitaxel (Taxol) is a potent antiproliferative agent that shifts the microtubule equilibrium toward assembly, favoring the formation of abnormally stable microtubules with blockage of the cell cycle in G2/M phases. A series of clinical trials (TAXUS I through VI) have been designed to test the safety and the efficacy of polymer-based paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, MA, USA) at the dosage 1 μg/mm2 in a variety of clinical settings. Except for TAXUS III and TAXUS V-ISR, in the TAXUS program de novo lesions have been evaluated. Two different release kinetics were evaluated: slow-release (SR) and moderate-release (MR) formulation. Very encouraging preliminary results also come from the "real world" data on Taxus SR stent collected in the "Web-based taxus Intercontinental observational Data TransitiOnal registry program" (the WISDOM Registry) and in the "Real Life Polymer-Based Paclitaxel Registry" (the Real Life PBPaclitaxel Registry). The remarkable positive results obtained from the randomized trials offer the interventional cardiologist another effective option (besides the Cypher stent, Cordis a J & J, Warren, NJ, USA) to treat patients with a DES. This fact may certainly drive the competition and, ultimately, lower the cost. The final answer will probably come from the ongoing registries and prospective trials versus coronary artery bypass grafting (CABG), which will reveal the real impact of this new technology on everyday practice.

KW - De novo lesions

KW - Paclitaxel-eluting stents

KW - Restenosis

UR - http://www.scopus.com/inward/record.url?scp=1942488277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942488277&partnerID=8YFLogxK

U2 - 10.1007/s00059-004-2555-7

DO - 10.1007/s00059-004-2555-7

M3 - Article

VL - 29

SP - 147

EP - 151

JO - Herz

JF - Herz

SN - 0340-9937

IS - 2

ER -